PHYSICIAN PAYMENTS SUNSHINE ACT (OPEN PAYMENTS) Mary Evelyn Armstrong MA, CRA Conflict of Interest Officer

Size: px
Start display at page:

Download "PHYSICIAN PAYMENTS SUNSHINE ACT (OPEN PAYMENTS) Mary Evelyn Armstrong MA, CRA Conflict of Interest Officer"

Transcription

1 PHYSICIAN PAYMENTS SUNSHINE ACT (OPEN PAYMENTS) Mary Evelyn Armstrong MA, CRA Conflict of Interest Officer

2 WHAT IS IT? Section 6002 of the Affordable Care Act requires the establishment of a transparency program, now known as Open Payments. The program increases public awareness of financial relationships between drug and device manufacturers and certain health care providers through annual reporting on a public website.

3 HOW DOES IT WORK? Manufacturers and Group Purchasing Organizations (GPO s) will report to CMS every year: 1. Payments and other transfers of value to physicians and teaching hospitals ( Covered Recipients ) 2. Ownerships or investments held by physicians or their immediate family in manufacturers and GPOs The reported data will be published June 30th each year on a public website and will include payments from the previous calendar year Review and dispute 45 days to review and dispute incorrect data Additional 15 days to resolve dispute If not resolved, will still be published and flagged as disputed

4 WHO DOES THIS APPLY TO? Covered Recipients Physicians who are legally authorized to practice: Doctors of Medicine, Osteopathy, Dentistry, Dental Surgery, Podiatry, Optometry, Chiropractic Medicine Does not include Residents Teaching Hospitals Receive payment under Medicare direct graduate medical education (GME), inpatient hospital prospective payment system (IPPS), indirect medical education (IME), or psychiatric hospital IME programs

5 WHAT IS REPORTED? All payments or other transfers of value Amount of payment Date of payment Nature of payment Form of payment Related products (drug, device, biological or medical supply) Physician information: Name, specialty, business address, NPI, State professional license number(s) Research payments will be reported separately from general payments and ownership/investment interests.

6 WHAT IS REPORTED? Ownership or investment interests held by physicians or their immediate family members Physician information: Name, specialty, business address, NPI, State professional license number(s) Dollar amount of the investment Value and terms of the ownership or investment interest

7 NATURE OF PAYMENT Consulting fees Compensation for services other than consulting, including serving as faculty or as a speaker at an event other than a continuing education program Honoraria Gifts Entertainment Food and beverage Travel and lodging Education Research Charitable contributions Royalty or license Current or prospective ownership or investment interest Compensation for serving as faculty or as a speaker for an unaccredited and non-certified continuing education program Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program Grants Space rental or facility fees (teaching hospital only)

8 NATURE OF PAYMENT: FOOD & BEVERAGE Group settings Total cost divided by number of individuals who partook in the meal and reported for covered recipients only Meals eaten by support staff are not attributed to physicians Conferences and large events When the setting would make it difficult to establish the identities of covered recipients, not reportable (e.g., buffet meals at conferences)

9 NATURE OF PAYMENT: RESEARCH Information reported: Name of Institution receiving the payment Total amount of the research payment Aggregated amount of payment for everything included in the written agreement Payments made outside of agreement are reported separately in the appropriate nature of payment category (e.g., additional fees for study steering committee) Research payments will not be aggregated on database as personal payments to physicians Name of the study Name of the related covered product Principal Investigator(s) ClinicalTrials.gov identifier (optional)

10 NATURE OF PAYMENT: RESEARCH Research delays in publication: Manufacturers (or GPOs) may request a delay in publication Research on or development of new products/new product applications Clinical investigations regarding a new product (written research or development agreement is required) Publication is delayed until (whichever comes first): Date of FDA approval, licensure or clearance of the product 4 calendar years after the date of the payment or other transfer of value

11 FORM OF PAYMENT Cash or cash equivalent In-kind items or services Stock or stock options or any other ownership interest Dividend, profit or other return on investment

12 TYPES OF PAYMENT Direct payments - Payments or other transfers of value provided directly to physicians or teaching hospitals. Indirect payments Payments or other transfers of value made through an intermediary. Manufacturer (or GPO) requires, instructs, directs, or otherwise causes the third party to provide the payment to a physician or teaching hospital. Third party payments - Payments or other transfers of value provided to a third party at the request of or designated on behalf of a physician or teaching hospital.

13 WHAT IS NOT REPORTED? Indirect payments where the applicable manufacturer is unaware of recipient Payments under $10, unless over $100 in aggregate Samples Educational materials for patients Short term loans defined as 90 days (equipment, devices, supplies) Items or services under warranty Transfers of value to a physician who is a patient or research subject Discounts and rebates In-kind items for use in charity care Dividends from publicly traded securities or mutual funds

14 WHAT IS NOT REPORTED? Payments to provide healthcare for employees/families Non-medical professional services of a physician Legal services of a physician Personal, non-business related transfers of value

15 WHAT SHOULD YOU DO? Operate within University policies, including full disclosure of activities and adherence to allowable and prohibited activities. Relevant policies include: Industry Relations Policy Prohibits speakers bureaus; promotional/marketing activities; receipt of food and gifts MUSC/MUHA Conflict of Interest Policy MUSC Intellectual Property Policy (Section of the MUSC Faculty Handbook) Keep track of payments and transfers of value made to you. Mobile app is available - OPEN PAYMENTS Mobile for Physicians Be mindful of ownership and investment interests held by you and immediate family members.

16 WHAT SHOULD YOU DO? Ask companies to let you review reportable transfers before they report them. Verify your information in the NPI enumerator database is current and update as needed. Register with CMS in order to receive notifications and information. Review your information for accuracy.

17 RESOURCES ama-assn.org/go/sunshine COI Office: Mary Evelyn Armstrong

FOR PHYSICIANS. CMS will collect the data annually, aggregate it, and publish it on a public website.

FOR PHYSICIANS. CMS will collect the data annually, aggregate it, and publish it on a public website. Open Payments (Physician Payments Sunshine Act) Why Open Payments is Important to You Section 6002 of the Affordable Care Act requires the establishment of a transparency program, now known as Open payments.

More information

The Physician Payments Sunshine Law and you: Building stronger industry - physician interactions

The Physician Payments Sunshine Law and you: Building stronger industry - physician interactions The Physician Payments Sunshine Law and you: Building stronger industry - physician interactions 1 What is the timing of the Sunshine Law requirements? Aug. 1, 2013: Manufacturers are required to begin

More information

HCCA CLINICAL PRACTICE COMPLIANCE CONFERENCE

HCCA CLINICAL PRACTICE COMPLIANCE CONFERENCE HCCA CLINICAL PRACTICE COMPLIANCE CONFERENCE CMS Open Payments Formerly Known as the Sunshine Act October 13, 2014 Philadelphia, Pennsylvania PRESENTATION OBJECTIVES Open Payment Regulations Reporting

More information

Know, Prepare and Comply with the Sunshine Act Phase 2. John A. Murphy, III, Assistant General Counsel PhRMA August 26, 2014

Know, Prepare and Comply with the Sunshine Act Phase 2. John A. Murphy, III, Assistant General Counsel PhRMA August 26, 2014 Know, Prepare and Comply with the Sunshine Act Phase 2 John A. Murphy, III, Assistant General Counsel PhRMA August 26, 2014 Sponsored by: HCIdea provides the most accurate Physician data (NPIs and State

More information

Shedding Light on the Sunshine Act

Shedding Light on the Sunshine Act Shedding Light on the Sunshine Act February 28, 2013 Jean C. Hemphill hemphill@ballardspahr.com 215.864.8539 Mary J. Mullany mullany@ballardspahr.com 215.864.8631 Copyright 2013 by Ballard Spahr LLP Program

More information

FACT SHEET. The Physician Payments Sunshine Act: CMS Proposed Rule

FACT SHEET. The Physician Payments Sunshine Act: CMS Proposed Rule FACT SHEET The Physician Payments Sunshine Act: CMS Proposed Rule Executive Summary: CMS is making rules to implement sections of the Patient Protection and Affordable Care Act that would require eye banks

More information

Frequently Asked Questions (FAQs) regarding the. National Physician Payment Transparency Program (Open Payments)

Frequently Asked Questions (FAQs) regarding the. National Physician Payment Transparency Program (Open Payments) Frequently Asked Questions (FAQs) regarding the National Physician Payment Transparency Program (Open Payments) [initiated by the Physician Payments Transparency Act (PPSA)] These FAQs are intended as

More information

Physician Payments Sunshine Act Final Rule ACA Section 6002

Physician Payments Sunshine Act Final Rule ACA Section 6002 Physician Payments Sunshine Act Final Rule ACA Section 6002 Program Overview Applicable manufacturers and applicable GPOs collect information on payments and/or ownership interests for an entire calendar

More information

MEMORANDUM. Bob Saner, MGMA Washington Counsel and Johanna Michaels Kreisel, Attorneys in the Powers Law Firm

MEMORANDUM. Bob Saner, MGMA Washington Counsel and Johanna Michaels Kreisel, Attorneys in the Powers Law Firm MEMORANDUM To: From: MGMA Bob Saner, MGMA Washington Counsel and Johanna Michaels Kreisel, Attorneys in the Powers Law Firm Date: May 1, 2013 Re: Final Rule Implementing the Physician Payments Sunshine

More information

CMS ISSUES FINAL RULE FOR IMPLEMENTING SUNSHINE ACT. Executive Summary

CMS ISSUES FINAL RULE FOR IMPLEMENTING SUNSHINE ACT. Executive Summary WSGR ALERT FEBRUARY 2013 CMS ISSUES FINAL RULE FOR IMPLEMENTING SUNSHINE ACT On February 8, 2013, 16 months after the statutory deadline, the Centers for Medicare & Medicaid Services (CMS) published in

More information

Web Seminar. Physician Payments in the "Sunshine": Implications of CMS Regulations for Business and the Future of American Health Care.

Web Seminar. Physician Payments in the Sunshine: Implications of CMS Regulations for Business and the Future of American Health Care. Web Seminar Physician Payments in the "Sunshine": Implications of CMS Regulations for Business and the Future of American Health Care Featuring James C. Stansel Sidley Austin LLP Meenakshi Datta Sidley

More information

Association of Corporate Counsel January 2012 Teleconference CMS Finally Issues Proposed Sunshine Act Regulations

Association of Corporate Counsel January 2012 Teleconference CMS Finally Issues Proposed Sunshine Act Regulations 1 Association of Corporate Counsel January 2012 Teleconference CMS Finally Issues Proposed Sunshine Act Regulations January 3, 2012 Judy Waltz, Partner Foley & Lardner LLP 2012 Foley & Lardner LLP Attorney

More information

Physician Payment Sunshine Provisions in Healthcare Reform Prepared by AAMC Government Relations Revised May 28, 2010

Physician Payment Sunshine Provisions in Healthcare Reform Prepared by AAMC Government Relations Revised May 28, 2010 Physician Payment Sunshine Provisions in Healthcare Reform Prepared by AAMC Government Relations Revised May 28, 2010 Section 6002 of the Patient Protection and Affordable Care Act [P.L. 110-148] amends

More information

Frequently Asked Questions

Frequently Asked Questions Medical Imaging and Technology Alliance (MITA) Fact Sheet on Federal and State Medical Device Marketing or Sunshine Disclosure Laws Updated November 16, 2011 A new federal law called the Federal Physician

More information

Welcome to the Lex Mundi Learning Network. Understanding the New U.S. Sunshine Act and Its Impact on Health Care Providers and Industry

Welcome to the Lex Mundi Learning Network. Understanding the New U.S. Sunshine Act and Its Impact on Health Care Providers and Industry Welcome to the Lex Mundi Learning Network Understanding the New U.S. Sunshine Act and Its Impact on Health Care Providers and Industry Colin Zick, Foley Hoag LLP Pat Cerundolo, Foley Hoag LLP Bill McKenzie,

More information

CENTERS FOR MEDICARE & MEDICAID SERVICES (CMS) OPEN PAYMENT FREQUENTLY ASKED QUESTIONS (FAQ) TRACKER. June attorney advertisement

CENTERS FOR MEDICARE & MEDICAID SERVICES (CMS) OPEN PAYMENT FREQUENTLY ASKED QUESTIONS (FAQ) TRACKER. June attorney advertisement CENTERS FOR MEDICARE & MEDICAID SERVICES (CMS) OPEN PAYMENT FREQUENTLY ASKED QUESTIONS (FAQ) TRACKER June 2014 attorney advertisement 2014 Cooley LLP Five Palo Alto Square, 3000 El Camino Real, Palo Alto,

More information

CENTERS FOR MEDICARE & MEDICAID SERVICES (CMS) OPEN PAYMENT FREQUENTLY ASKED QUESTIONS (FAQ) TRACKER

CENTERS FOR MEDICARE & MEDICAID SERVICES (CMS) OPEN PAYMENT FREQUENTLY ASKED QUESTIONS (FAQ) TRACKER CENTERS FOR MEDICARE & MEDICAID SERVICES (CMS) OPEN PAYMENT FREQUENTLY ASKED QUESTIONS (FAQ) TRACKER Current as of 12, attorney advertisement Cooley LLP Five Palo Alto Square, 3000 El Camino Real, Palo

More information

Open Payments Law Overview. University of Alabama at Birmingham University Compliance Office

Open Payments Law Overview. University of Alabama at Birmingham University Compliance Office Open Payments Law Overview University of Alabama at Birmingham University Compliance Office What is the Open Payments Law? Federal law (formerly known as Physician Payment Sunshine Act ) signed into effect

More information

Open Payments An Explanation of Section 6002 of the Affordable Care Act

Open Payments An Explanation of Section 6002 of the Affordable Care Act Open Payments An Explanation of Section 6002 of the Affordable Care Act Center for Program Integrity February, 2014 CMS Disclaimer: This information is a summary of sections of the NPPTP. This information

More information

KEY CHANGES IN THE FINAL PHYSICIAN PAYMENT SUNSHINE ACT REGULATIONS. Association of Corporate Counsel Legal Quick Hit May 30, 2013.

KEY CHANGES IN THE FINAL PHYSICIAN PAYMENT SUNSHINE ACT REGULATIONS. Association of Corporate Counsel Legal Quick Hit May 30, 2013. 1 KEY CHANGES IN THE FINAL PHYSICIAN PAYMENT SUNSHINE ACT REGULATIONS Association of Corporate Counsel Legal Quick Hit May 30, 2013 Maria E. Gonzalez Knavel Partner Foley & Lardner LLP 414.297.5649 mgonzalezknavel@foley.com

More information

CENTERS FOR MEDICARE & MEDICAID SERVICES (CMS) OPEN PAYMENT FREQUENTLY ASKED QUESTIONS (FAQ) TRACKER

CENTERS FOR MEDICARE & MEDICAID SERVICES (CMS) OPEN PAYMENT FREQUENTLY ASKED QUESTIONS (FAQ) TRACKER CENTERS FOR MEDICARE & MEDICAID SERVICES (CMS) OPEN PAYMENT FREQUENTLY ASKED QUESTIONS (FAQ) TRACKER Current as of 12, attorney advertisement Cooley LLP Five Palo Alto Square, 3000 El Camino Real, Palo

More information

Title Final Sunshine Act Arrives: Now the Hard Part

Title Final Sunshine Act Arrives: Now the Hard Part Title Final Sunshine Act Arrives: Now the Hard Part January 2013 March 2013 www.morganlewis.com 1 2013 Morgan, Lewis & Bockius LLP The Centers for Medicare and Medicaid Services (CMS) issued the final

More information

The Physician Payment Sunshine Act Final Rule A Summary Of Key Provisions

The Physician Payment Sunshine Act Final Rule A Summary Of Key Provisions The Physician Payment Sunshine Act Final Rule A Summary Of Key Provisions On February 1, 2013, Centers for Medicare and Medicaid Services (CMS) published the long-awaited Physician Payment Sunshine Act

More information

Physician Payments Sunshine Act Proposed Rule Published

Physician Payments Sunshine Act Proposed Rule Published Physician Payments Sunshine Act Proposed Rule Published Kim Kannensohn Krist Werling Holly Carnell www.mcguirewoods.com McGuireWoods news is intended to provide information of general interest to the public

More information

SIDE-BY-SIDE OF THE PHYSICIAN PAYMENTS SUNSHINE ACT

SIDE-BY-SIDE OF THE PHYSICIAN PAYMENTS SUNSHINE ACT Provision Amends Implementation Date Who must disclose? Reporting Frequency Grassley 2008 bill Grassley/Kohl bill Patient Protection and revised (S.301), 111 th Affordable Care Act (MAL08221) Congress

More information

Shedding Light on the U.S. and French Sunshine Laws

Shedding Light on the U.S. and French Sunshine Laws Shedding Light on the U.S. and French Sunshine Laws Teleseminar September 17, 2014 Elizabeth Carder-Thompson, Washington, D.C. & Princeton, N.J. Daniel Kadar, Paris Overview of Discussion Origins and implementation

More information

Physician Payment Transparency Provisions of the Affordable Care Act Sunshine 101

Physician Payment Transparency Provisions of the Affordable Care Act Sunshine 101 Physician Payment Transparency Provisions of the Affordable Care Act Sunshine 101 Danielle Drissel, Associate February 19, 2013 Health/ Washington DC What is Sunshine? Deceptively simple: Applicable manufacturers

More information

Latham & Watkins Corporate and Litigation Departments. CMS Issues Proposed Regulations Interpreting the Physician Payment Sunshine Act

Latham & Watkins Corporate and Litigation Departments. CMS Issues Proposed Regulations Interpreting the Physician Payment Sunshine Act Number 1266 December 19, 2011 Client Alert Latham & Watkins Corporate and Litigation Departments CMS Issues Proposed Regulations Interpreting the Physician Payment Sunshine Act CMS estimates the average

More information

Physician Payment Sunshine Provisions of the Affordable Care Act Comparison of the Key Provisions Proposed and Final Rule Arnold & Porter LLP

Physician Payment Sunshine Provisions of the Affordable Care Act Comparison of the Key Provisions Proposed and Final Rule Arnold & Porter LLP I. Key Provisions that Shape the Obligation to Report Payments and Other Transfers of Value Under SSA 1128G(a)(1) The statute and regulations require the reporting of payments or other transfers of value

More information

Transparency reports (Sunshine Act)

Transparency reports (Sunshine Act) Transparency reports (Sunshine Act) Summary: Requires drug, device, biological and medical supply manufacturers to report transfers of value made to a physician or a teaching hospital. Duplicative State

More information

AHLA. LL. Out in the Sunshine How to Protect Yourself

AHLA. LL. Out in the Sunshine How to Protect Yourself AHLA LL. Out in the Sunshine How to Protect Yourself Jolee Hancock Bollinger General Counsel Franciscan Missionaries of Our Lady Health System Baton Rouge, LA Andrew D. Ruskin Morgan Lewis & Bockius LLP

More information

Is the Sunshine Act the. support? John P. Gonzalez Director of Publications Policy AstraZeneca

Is the Sunshine Act the. support? John P. Gonzalez Director of Publications Policy AstraZeneca Is the Sunshine Act the twilight of pharmasponsored medical writing support? John P. Gonzalez Director of Publications Policy AstraZeneca Conflict of interest disclosure I am a full time employee of AstraZeneca

More information

Understanding the Forces Driving Disclosure

Understanding the Forces Driving Disclosure Understanding the Forces Driving Disclosure March 3, 2010 Jeffrey L. Handwerker Forces Behind the Trend Toward Disclosure State Laws/Legislatures/NLARx Academic Institutions Voluntary Changes in Company

More information

Physician Payments Sunshine Provisions in Healthcare Reform Tracking and Monitoring Spending on Healthcare Professionals and Organizations

Physician Payments Sunshine Provisions in Healthcare Reform Tracking and Monitoring Spending on Healthcare Professionals and Organizations Physician Payments Sunshine Provisions in Healthcare Reform Tracking and Monitoring Spending on Healthcare Professionals and Organizations Background Consumer advocates and the media have commented in

More information

The Sunshine Act: Where it stands, where it s going and compliance implementation

The Sunshine Act: Where it stands, where it s going and compliance implementation The Sunshine Act: Where it stands, where it s going and compliance implementation PRESENTED BY: Stacey A. Filice Jazz Pharmaceuticals Disclaimer slide The views expressed in this presentation are my own

More information

Client Alert. CMS Announces Final Regulations Interpreting the Physician Payment Sunshine Act. A. Definitions and Exclusions

Client Alert. CMS Announces Final Regulations Interpreting the Physician Payment Sunshine Act. A. Definitions and Exclusions Number 1469 February 18, 2013 Client Alert Latham & Watkins Corporate Department CMS Announces Final Regulations Interpreting the Physician Payment Sunshine Act To avoid significant penalties for non-compliance,

More information

Section 6004: Prescription Drug Sample Transparency. Section 6005: Pharmacy Benefit Managers Transparency Requirements

Section 6004: Prescription Drug Sample Transparency. Section 6005: Pharmacy Benefit Managers Transparency Requirements Legislative text of Physician Payment and other transparency provisions included in H.R. 0: Patient Protection and Affordable Care Act of 0 Passed by the Senate (//0) and the House (//) Section 00: Transparency

More information

Bill Moran and Betta Sherman

Bill Moran and Betta Sherman Compliance TODAY July 2013 a publication of the health care compliance association www.hcca-info.org How an eye doctor s son sees compliance an interview with Stephen Kiess Assistant General Counsel for

More information

Ministry of Health and Long-Term Care Proposed new regulation made under the Health Sector Payment Transparency Act, 2017

Ministry of Health and Long-Term Care Proposed new regulation made under the Health Sector Payment Transparency Act, 2017 Ministry of Health and Long-Term Care Proposed new regulation made under the Health Sector Payment Transparency Act, 2017 The Health Sector Payment Transparency Act, 2017 (HSPTA) is new legislation intended

More information

Patient Protection and Affordable Care Act (P.L ) Titles VI through X

Patient Protection and Affordable Care Act (P.L ) Titles VI through X Patient Protection and Affordable Care Act (P.L. 111-148) Titles VI through X As enacted March 23, 2010 The following pages contain the text of Titles VI through X of the Patient Protection and Affordable

More information

FINANCIAL CONFLICT OF INTEREST POLICY

FINANCIAL CONFLICT OF INTEREST POLICY FINANCIAL CONFLICT OF INTEREST POLICY Individuals who are appointed to serve on ABIM boards or committees are expected to have the American Board of Internal Medicine s (ABIM) mission as their primary

More information

P harmaceutical and medical device manufacturers

P harmaceutical and medical device manufacturers BNA s Health Care Fraud Report Reproduced with permission from Health Care Fraud Report, 16 HFRA 80, 01/25/2012. Copyright 2012 by The Bureau of National Affairs, Inc. (800-372-1033) http://www.bna.com

More information

Conflicts of Interest

Conflicts of Interest Conflicts of Interest What happens when what is reported to you does not match what is reported by or to others. HCCA Compliance Institute April 22, 2013 Session 111 Marti Arvin, Chief Compliance Officer,

More information

ONTARIO REGULATION to be made under the

ONTARIO REGULATION to be made under the Caution: This consultation draft is intended to facilitate dialogue concerning its contents. Should the decision be made to proceed with the proposal, the comments received during consultation will be

More information

Industry Funding of Continuing Medical Education

Industry Funding of Continuing Medical Education Industry Funding of Continuing Medical Education June 25, 2010 Julie K. Taitsman, M.D., J.D. Chief Medical Officer, Office of Inspector General U.S. Department of Health and Human Services Financial Relationships

More information

Journal of Clinical Oncology Author Submission preparation worksheet. Author Disclosure Declaration

Journal of Clinical Oncology Author Submission preparation worksheet. Author Disclosure Declaration Journal of Clinical Oncology Author Submission preparation worksheet Each author should complete and return this form to the corresponding author. FOR REFERENCE ONLY DO NOT SEND TO JCO Author Disclosure

More information

Continuing Medical Education (CME) Programs: Compliance Guide for Sunshine Rule

Continuing Medical Education (CME) Programs: Compliance Guide for Sunshine Rule July 25, 2013 Continuing Medical Education (CME) Programs: Compliance Guide for Sunshine Rule This document represents our considered judgment based on our regulatory expertise in these matters. It is

More information

Strategic and Operational Challenges Resulting from the New PPACA

Strategic and Operational Challenges Resulting from the New PPACA Strategic and Operational Challenges Resulting from the New PPACA Eric M. Baim, Esq., Hogan Lovells Jennifer Colapietro, Partner, PwC Thursday, October 21, 2010 The Big Questions Who s in charge here?

More information

ANCILLARY services: How to Stay Out of Trouble. The neurosurgical minefield Informed consent

ANCILLARY services: How to Stay Out of Trouble. The neurosurgical minefield Informed consent ANCILLARY services: How to Stay Out of Trouble Richard N.W. Wohns, M.D. JD, MBA NeoSpine, Puget Sound Region, Washington The neurosurgical minefield 2013 Informed consent HIPAA ARRA and HITECH Anti-Kickback

More information

Sunshine and Aggregate Spend

Sunshine and Aggregate Spend Sunshine and Aggregate Spend Challenges and Leading Practices in Reporting Clinical Spend Sixth Annual Summit on Disclosure, Transparency and Aggregate Spend for Drug, Device and Biotech Companies February

More information

Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018

Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018 NV ASTRAZENECA SA BE 0400.165.679 110, rue Egide Van Ophemstraat B-1180 Brussels Belgium Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018 Contents

More information

The Life Sciences Report

The Life Sciences Report S P R I N G 2 0 1 3 The Life Sciences Report Best Patent Practices Under the America Invents Act By Charles Andres, Associate (Washington, D.C.), Esther Kepplinger, Chief Patent Counselor (Washington,

More information

research must complete, even if they have used the coi.asco.org system)

research must complete, even if they have used the coi.asco.org system) JCO Precision Oncology Author Submission Preparation Worksheet FOR REFERENCE ONLY DO NOT SEND TO JCO PO This worksheet contains: 1. Author Disclosure Form (Authors who do not use the coi.asco.org system

More information

Policy on Conflicts of Interest in Clinical Care

Policy on Conflicts of Interest in Clinical Care Policy on Conflicts of Interest in Clinical Care Approved by FPP Board of Directors: March 16, 2006 Revised and Approved: December 15, 2009, January 18, 2011, January 22, 2013, January 21, 2014, April

More information

Gifts to Referral Sources. Kim C. Stanger (11-17)

Gifts to Referral Sources. Kim C. Stanger (11-17) Gifts to Referral Sources Kim C. Stanger (11-17) Overview Some relevant laws Applying those laws to common situations Gifts to or from referral sources Gifts to physicians Gifts to or from patients Gifts

More information

CONFLICTS OF INTEREST IN RESEARCH

CONFLICTS OF INTEREST IN RESEARCH IM&COI POLICY III CONFLICTS OF INTEREST IN RESEARCH (Capitalized terms are defined in the Glossary.) Presumption Against Participating in Research When Personal Financial Interests Exist If an Investigator

More information

DOCUMENT HISTORY. Supersedes / Replaces. Version Effective Date Summary of Changes 01 30JUN2017 New Methodological Note

DOCUMENT HISTORY. Supersedes / Replaces. Version Effective Date Summary of Changes 01 30JUN2017 New Methodological Note Document Title Methodological Note EFPIA Disclosure of Transfers of Value to Healthcare Professionals and Organisations ( Methodological Note on Disclosure ) Document Version 01 Effective Date 30JUN2017

More information

Do Start Believin': The Life Sciences Industry's Journey to Global Transparency

Do Start Believin': The Life Sciences Industry's Journey to Global Transparency Do Start Believin': The Life Sciences Industry's Journey to Global Transparency D. Jeffrey Campbell, Esq. Brian P. Sharkey, Esq. Porzio Life Sciences, LLC August 2014 Do Start Believin': 1 The Life Sciences

More information

Weill Cornell Medical College Study Specific Form FOR EXTERNAL NON-WCMC USE ONLY. Study Specific Report Form

Weill Cornell Medical College Study Specific Form FOR EXTERNAL NON-WCMC USE ONLY. Study Specific Report Form Weill Cornell Medical College Study Specific Form FOR EXTERNAL NON-WCMC USE ONLY All external users must complete an external SSR whether or not they have any relationships to disclose. * Investigators

More information

Graduate Medical Education Medical Industry Interaction Policy and Procedure. December 18, 2008

Graduate Medical Education Medical Industry Interaction Policy and Procedure. December 18, 2008 Graduate Medical Education Medical Industry Interaction Policy and Procedure December 18, 2008 Purpose: To ensure that all residents and fellows interactions with representatives of the pharmaceutical

More information

The Effect of the Sunshine Act on Industry Payments to Physicians in Orthopedic Surgery and Other Surgical Specialties

The Effect of the Sunshine Act on Industry Payments to Physicians in Orthopedic Surgery and Other Surgical Specialties Yale University Department of Economics Undergraduate Program The Effect of the Sunshine Act on Industry Payments to Physicians in Orthopedic Surgery and Other Surgical Specialties Senior Thesis Tijana

More information

VENDOR PROGRAM. Vendors must complete the Vendor Screening and Disclosure Form as follows: *must be completed prior to any signed purchase order

VENDOR PROGRAM. Vendors must complete the Vendor Screening and Disclosure Form as follows: *must be completed prior to any signed purchase order VENDOR PROGRAM 1. PURPOSE The purpose of this policy is to outline the standards that the Hospital utilizes in evaluating which vendors to contract with, the standards for contracting, and the code of

More information

PPACA and Physicians: Payment, Quality, Program Integrity

PPACA and Physicians: Payment, Quality, Program Integrity PPACA and Physicians: Payment, Quality, Program Integrity Mary Patton mpatton@aamc.org Ivy Baer ibaer@aamc.org Dave Moore dbmoore@aamc.org AAMC Teleconference April 27, 2009 Agenda Physician Payment &

More information

DOCUMENT HISTORY. Supersedes / Replaces. Version Effective Date Summary of Changes 01 30JUN2016 New Methodological Note

DOCUMENT HISTORY. Supersedes / Replaces. Version Effective Date Summary of Changes 01 30JUN2016 New Methodological Note Document Title Methodological Note EFPIA Disclosure of Transfers of Value to Healthcare Professionals and Organisations in Poland ( Methodological Note on Disclosure ) Document Version 01 Effective Date

More information

College of Medicine Policy on Pharmaceutical, Medical Device, and Biotechnology. (1) Definitions. The following definitions apply to this regulation:

College of Medicine Policy on Pharmaceutical, Medical Device, and Biotechnology. (1) Definitions. The following definitions apply to this regulation: College of Medicine Policy on Pharmaceutical, Medical Device, and Biotechnology Industry Conflict of Interest (1) Definitions. The following definitions apply to this regulation: (a) COM means the University

More information

Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018

Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018 Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018 AstraZeneca Pharmaceuticals (Ireland) DAC, Company registration number: 55502 Ireland, Address of

More information

Medicare Part C Medical Coverage Policy

Medicare Part C Medical Coverage Policy Medicare Part C Medical Coverage Policy Investigational (Experimental) Services Origination: November 2009 Review Date: July 12, 2017 Next Review: July 2019 DESCRIPTION OF PROCEDURE OR SERVICE Title XVIII

More information

REGULATIONS OF THE UNIVERSITY OF FLORIDA College of Medicine Policy on Pharmaceutical, Medical Device, and

REGULATIONS OF THE UNIVERSITY OF FLORIDA College of Medicine Policy on Pharmaceutical, Medical Device, and REGULATIONS OF THE UNIVERSITY OF FLORIDA 5.0764 College of Medicine Policy on Pharmaceutical, Medical Device, and Biotechnology Industry Conflicts of Interest (1) Definitions. The following definitions

More information

Pharmaceutical Compliance Congress: State of the States

Pharmaceutical Compliance Congress: State of the States Pharmaceutical Compliance Congress: State of the States October 27, 2008 Janice G. Cunningham Jeffrey L. Handwerker Overview Types of State Laws Potentially Affected by the Sunshine Act Limits or Prohibitions

More information

Ch. 127 MEDICAL COST CONTAINMENT CHAPTER 127. WORKERS COMPENSATION MEDICAL COST CONTAINMENT

Ch. 127 MEDICAL COST CONTAINMENT CHAPTER 127. WORKERS COMPENSATION MEDICAL COST CONTAINMENT Ch. 127 MEDICAL COST CONTAINMENT 34 127.1 CHAPTER 127. WORKERS COMPENSATION MEDICAL COST CONTAINMENT Subch. Sec. A. PRELIMINARY PROVISIONS... 127.1 B. MEDICAL FEES AND FEE REVIEW... 127.101 C. MEDICAL

More information

To: Vice Chancellors, Deans, Administrative Staff, Department Heads, and Students.

To: Vice Chancellors, Deans, Administrative Staff, Department Heads, and Students. Chancellor s Memorandum CM-35 Conflicts of Interest in Research: Managing Potential Financial and Non-Financial Conflicts of Interest of Individuals and the Institution To: Vice Chancellors, Deans, Administrative

More information

FREQUENTLY ASKED QUESTIONS SUNSHINE ACT

FREQUENTLY ASKED QUESTIONS SUNSHINE ACT FREQUENTLY ASKED QUESTIONS SUNSHINE ACT 1. What exactly is the obligation of transparency? The obligation of transparency imposes pharmaceutical and medical devices companies, both Belgian and foreign,

More information

Introduction. Incentive Payments for. Health Care Regulatory and Compliance Insights. Daniel F. Gottlieb, Esq.

Introduction. Incentive Payments for. Health Care Regulatory and Compliance Insights. Daniel F. Gottlieb, Esq. Health Care Regulatory and Compliance Insights CMS Proposes Medicare and Medicaid Reimbursement Rules for Earning Incentive Payments for Meaningful Use of Certified Electronic Health Record Technology

More information

Columbia University MORNINGSIDE ANNUAL CONFLICT OF INTEREST DISCLOSURE STATEMENT

Columbia University MORNINGSIDE ANNUAL CONFLICT OF INTEREST DISCLOSURE STATEMENT Columbia University MORNINGSIDE ANNUAL CONFLICT OF INTEREST DISCLOSURE STATEMENT This information applies to current activities and any activities anticipated during the next 12 months. NOTE: All underlined

More information

Creation Date: 7/1/01 Title: Conflict of Interest Revision History:

Creation Date: 7/1/01 Title: Conflict of Interest Revision History: RENOWN HEALTH Policies & Procedures Page 1 of 6 Current Version Effective Date: 8/16/17 Creation Date: 7/1/01 Title: Conflict of Interest Revision History: Type: Number: Author(s): Owner: Compliance RENOWN.CCD.500

More information

Stark and the Anti Kickback Statute. Regulating Referral Relationship. February 27-28, HCCA Board Audit Committee Compliance Conference.

Stark and the Anti Kickback Statute. Regulating Referral Relationship. February 27-28, HCCA Board Audit Committee Compliance Conference. Stark and the Anti Kickback Statute Ryan Meade, JD, CHRC, CHC F Director, Regulatory Compliance Studies Beazley Institute for Health Law and Policy Loyola University Chicago School of Law rmeade@luc.edu

More information

Transfer of Value Disclosure Report as per National Legislation

Transfer of Value Disclosure Report as per National Legislation Merz Pharmaceuticals GmbH Methodological Note Transfer of Value Disclosure Report as per National Legislation 1 I) Introductory note Merz supports laws and obligations which promote transparency around

More information

Government, Industry and Health Profession Compliance Guidance: Welcome to the Era of Ethics and Transparency

Government, Industry and Health Profession Compliance Guidance: Welcome to the Era of Ethics and Transparency Government, Industry and Health Profession Compliance Guidance: Welcome to the Era of Ethics and Transparency Seton Hall Law School Healthcare Compliance Certification Program June 2010 Kathleen McDermott

More information

Fifth Annual National Congress on Health Care Compliance. Pharmaceutical Sales and Marketing: Are You Afraid to Look Under the Rocks?

Fifth Annual National Congress on Health Care Compliance. Pharmaceutical Sales and Marketing: Are You Afraid to Look Under the Rocks? Fifth Annual National Congress on Health Care Compliance Pharmaceutical Sales and Marketing: Are You Afraid to Look Under the Rocks? Michael P. Swiatocha February 8, 2002 Agenda Introduction - The US Pharmaceutical

More information

Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018

Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018 AstraZeneca Eesti OÜ Reg. kood 11733875 Järvevana tee 9 11314 Tallinn Estonia Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018 Contents 1. Introduction...

More information

340B Drug Pricing Program

340B Drug Pricing Program 340B Drug Pricing Program Mary Stepanyan, PharmD Candidate 2018 University of Southern California, School of Pharmacy Pro Pharma Pharmaceutical Consultants Under the preceptorship of Dr. Craig Stern WHY

More information

HONORARIA POLICY AND PROCEDURE

HONORARIA POLICY AND PROCEDURE HONORARIA POLICY AND PROCEDURE POLICY DESCRIPTION: continuing medical education Policy Governing Honoraria and Reimbursement of Expenses for physicians, and scientists in the role of invited speakers.

More information

Patient Resource Guide

Patient Resource Guide Access Services Patient Resource Guide AstraZeneca Access 360 is committed to helping you access our medicines. This guide will provide you with information and resources to help you understand how to

More information

CHAPTER 20 - MANAGED CARE HEALTH BENEFIT PLANS SECTION MANAGED CARE DEFINITIONS

CHAPTER 20 - MANAGED CARE HEALTH BENEFIT PLANS SECTION MANAGED CARE DEFINITIONS CHAPTER 20 - MANAGED CARE HEALTH BENEFIT PLANS SECTION.0100 - MANAGED CARE DEFINITIONS 11 NCAC 20.0101 SCOPE AND DEFINITIONS (a) Scope. (1) Sections.0200,.0300, and.0400 of this Chapter apply to HMOs,

More information

FREQUENTLY ASKED QUESTIONS SUNSHINE ACT

FREQUENTLY ASKED QUESTIONS SUNSHINE ACT FREQUENTLY ASKED QUESTIONS SUNSHINE ACT 1. What exactly is the obligation of transparency? The obligation of transparency imposes amongst others pharmaceutical and medical devices companies, both Belgian

More information

Stark/Anti- Kickback Fundamentals

Stark/Anti- Kickback Fundamentals Stark/Anti- Kickback Fundamentals HEALTHCON Business Expo April 2016 Presented by: Stacy Harper, JD, MHSA, CPC 1 Disclaimer This presentation is for general education purposes only. The information contained

More information

Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018

Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018 Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018 AstraZeneca Pharma Poland Sp. z o.o. 0000117902 Postepu 14, 02-676 Warsaw Contents 1. Introduction...

More information

Negotiating with Industry: What They Want vs. What We Need

Negotiating with Industry: What They Want vs. What We Need Negotiating with Industry: What They Want vs. What We Need Presented At: Massachusetts General Hospital October 19, 2017 Presented By: Partners Clinical Trials Office Maureen Lawton, Pharm.D., J.D. Michael

More information

Manufacturer Patient Support Initiatives: Current Practices and Recent Challenges. Andrew Ruskin Morgan Lewis

Manufacturer Patient Support Initiatives: Current Practices and Recent Challenges. Andrew Ruskin Morgan Lewis Intersecting Worlds of Drug, Device, Biologics and Health Law AHLA/FDLI May 22, 2012 Manufacturer Patient Support Initiatives: Current Practices and Recent Challenges by Andrew Ruskin Morgan Lewis The

More information

State Laws: Preemption, Enforcement, and Continued Requirements

State Laws: Preemption, Enforcement, and Continued Requirements 9th Annual Forum on Transparency & Aggregate Spend State Laws: Preemption, Enforcement, and Continued Requirements August 18, 2015 Brian A. Bohnenkamp King & Spalding LLP 202.626.5413 bbohnenkamp@kslaw.com

More information

MAIMONIDES MEDICAL CENTER SUBJECT: CONFLICTS OF INTEREST IN HUMAN RESEARCH & PHS FUNDED RESEARCH

MAIMONIDES MEDICAL CENTER SUBJECT: CONFLICTS OF INTEREST IN HUMAN RESEARCH & PHS FUNDED RESEARCH MAIMONIDES MEDICAL CENTER CODE: RES-021 (Reissued) ORIGINALLY ISSUED: October 22, 2009 SUBJECT: CONFLICTS OF INTEREST IN HUMAN RESEARCH & PHS FUNDED RESEARCH I. POLICY Consistent with current law and to

More information

RULES OF TENNESSEE DEPARTMENT OF LABOR AND WORKFORCE DEVELOPMENT DIVISION OF WORKERS COMPENSATION

RULES OF TENNESSEE DEPARTMENT OF LABOR AND WORKFORCE DEVELOPMENT DIVISION OF WORKERS COMPENSATION RULES OF TENNESSEE DEPARTMENT OF LABOR AND WORKFORCE DEVELOPMENT DIVISION OF WORKERS COMPENSATION CHAPTER 0800-02-06 GENERAL RULES OF THE WORKERS COMPENSATION PROGRAM TABLE OF CONTENTS 0800-02-06-.01 Definitions

More information

Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018

Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018 Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018 AstraZeneca Österreich GmbH Landstraßer Hauptstraße 1A, 1030 Wien Firmenbuch FN 51184x, HG Wien Contents

More information

American Thoracic Society International Conference SUMMARY AND DEFINITIONS OF ATS POLICIES ON CONFLICT OF INTEREST AND TOBACCO INDUSTRY RELATIONSHIPS

American Thoracic Society International Conference SUMMARY AND DEFINITIONS OF ATS POLICIES ON CONFLICT OF INTEREST AND TOBACCO INDUSTRY RELATIONSHIPS Please note: this document is intended as an optional resource for Conference organizers, chairs and presenters, as a summary of information made available on the ATS COI Website and ATS Website. If you

More information

Gilead Transparency Reporting Methodological Note

Gilead Transparency Reporting Methodological Note Gilead Transparency Reporting Methodological Note Contents 1 Introduction... 2 2 Definition of Transfers of Value... 2 3 Definition and management of Cross-Border Spend... 3 4 Which Recipients of Transfers

More information

Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018

Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018 Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018 ASTRAZENECA LUXEMBOURG SA N 2002 2220 862 AM BRILL 7B LU-3961 EHLANGE LUXEMBOURG Contents 1. Introduction...

More information

MEDICAL DEVICE REIMBURSEMENT PRESENTED AT ST. THOMAS UNIVERSITY, DESIGN AND MANUFACTURING IN THE MEDICAL DEVICE INDUSTRY COURSE ON SEPTEMBER 30, 2013

MEDICAL DEVICE REIMBURSEMENT PRESENTED AT ST. THOMAS UNIVERSITY, DESIGN AND MANUFACTURING IN THE MEDICAL DEVICE INDUSTRY COURSE ON SEPTEMBER 30, 2013 MEDICAL DEVICE REIMBURSEMENT PRESENTED AT ST. THOMAS UNIVERSITY, DESIGN AND MANUFACTURING IN THE MEDICAL DEVICE INDUSTRY COURSE ON SEPTEMBER 30, 2013 Presented by: Michael A. Sanchez, M.A., CCA Principal

More information

UNI Office of Research and Sponsored Programs Policy on Conflicts of Interest Involving Research Funded by the Public Health Service

UNI Office of Research and Sponsored Programs Policy on Conflicts of Interest Involving Research Funded by the Public Health Service UNI Office of Research and Sponsored Programs Policy on Conflicts of Interest Involving Research Funded by the Public Health Service 8-22-12 Purpose of Policy The purpose of this policy is to ensure that

More information

REPORT OF THE COUNCIL ON MEDICAL SERVICE. (J. Leonard Lichtenfeld, MD, Chair)

REPORT OF THE COUNCIL ON MEDICAL SERVICE. (J. Leonard Lichtenfeld, MD, Chair) REPORT OF THE COUNCIL ON MEDICAL SERVICE CMS Report -A-0 Subject: Presented by: Referred to: Appropriate Hospital Charges David O. Barbe, MD, Chair Reference Committee G (J. Leonard Lichtenfeld, MD, Chair)

More information

Cost Reporting Principles April 4, 2007

Cost Reporting Principles April 4, 2007 Reimbursement Primer for Compliance, Ethics and Legal Officers: Everything You Have Always Wanted to Know About Reimbursement but Were Afraid to Ask. Cost Reporting Principles April 4, 2007 Douglas J.

More information